
DCM Q4 FY26 Results Earnings Growth Outlook
Updated: 18 Mar 2026 • 9:15 am
Posted by:

DCM Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. DCM was listed on the National Stock Exchange (NSE) on 29-Mar-1995. DCM share has its face value of 10 per share, and its NSE symbol is DCM. The company operates in the Diversified sector and primarily belongs to the Diversified industry.
DCM Q4 Results 2026 Preview
- DCM Q4 FY26 revenue is expected to be around Recovery Outlook, representing a 12% YoY increase compared to the same quarter last year.
- Profit After Tax, or PAT, is projected to rise 11% YoY.
- EBITDA to rise 10%.
- DCM is expected to show Recovery Outlook in its revenue.
Click and Sign Up to Get Live Updates on Q4 Results
DCM Share Performance
- Over the past six months, DCM share price has Positive by 7% to .
- Moreover, over the past year, the stock has Positive by 12%
- Despite this weak short-term performance, DCM stock has delivered a financially sound 50% return over the past 5 years.
- As of today, 17-03-2026, the DCM share price is trading at per share.
Key Factors to Watch for DCM Q4 Results FY26
- Revenue Growth & Segment Performance – Focus on topline growth in the Diversified industry within the Diversified sector.
- Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
- Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
- Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
- Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.
About DCM
DCM operates diversified businesses including textiles chemicals and real estate focusing on operational efficiency and improving profitability.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Final Thoughts
DCM is gear up to announce its Q4 FY26 results. Analysts expect 12% revenue growth, a 11% rise in PAT, and a 10% rise in EBITDA. DCM focuses on revenue growth from order execution, margin improvement, a strong order book, and management.
Stay informed with Univest blogs to get real-time updates on DCM Q4 results FY26.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
California Software Company Q4 FY26 Preview: Revenue Growth Expectations and Earnings Outlook
The Byke Hospitality Q4 FY26 Preview: Revenue Growth Expectations and Earnings Outlook
Barak Valley Cements Q4 FY26 Preview: Revenue Growth Expectations and Earnings Outlook
Butterfly Gandhimathi Appliances Q4 FY26 Preview: Revenue Growth Expectations and Earnings Outlook
Shankara Buildpro Q4 FY26 Preview: Revenue Growth Expectations and Earnings Outlook
Recent Articles

Cohance Lifesciences Analyst Review May 2026
19 May 2026

NFP Sampoorna Foods IPO GMP Day 2 19 May 2026: GMP Rises to Rs 8, QIB Fully Subscribed, Retail at 0.65x — Closes Tomorrow
19 May 2026

Teamtech Formwork Solutions IPO GMP Day 1 19 May 2026: Zero GMP as Subscription Window Opens, Closes 21 May on NSE SME
19 May 2026

Rain Industries Analyst Review May 2026
19 May 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Recent Posts
Cohance Lifesciences Analyst Review May 2026
NFP Sampoorna Foods IPO GMP Day 2 19 May 2026: GMP Rises to Rs 8, QIB Fully Subscribed, Retail at 0.65x — Closes Tomorrow
Teamtech Formwork Solutions IPO GMP Day 1 19 May 2026: Zero GMP as Subscription Window Opens, Closes 21 May on NSE SME
Rain Industries Analyst Review May 2026
Finolex Cables Analyst Review May 2026
Popular this week
Cohance Lifesciences Analyst Review May 2026
NFP Sampoorna Foods IPO GMP Day 2 19 May 2026: GMP Rises to Rs 8, QIB Fully Subscribed, Retail at 0.65x — Closes Tomorrow
Teamtech Formwork Solutions IPO GMP Day 1 19 May 2026: Zero GMP as Subscription Window Opens, Closes 21 May on NSE SME
Rain Industries Analyst Review May 2026
Finolex Cables Analyst Review May 2026

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
